Agfa-Gevaert Valuation

Is AGE0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AGE0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AGE0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AGE0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AGE0?

Key metric: As AGE0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AGE0. This is calculated by dividing AGE0's market cap by their current revenue.
What is AGE0's PS Ratio?
PS Ratio	0.09x
Sales	€1.13b
Market Cap	€103.73m

AGE0 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.2x
Enterprise Value/EBITDA	8.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does AGE0's PS Ratio compare to its peers?

The above table shows the PS ratio for AGE0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.1x
AJ91 DocCheck	0.8x	n/a	€42.1m
M3V MeVis Medical Solutions	2.6x	n/a	€45.1m
COP CompuGroup Medical SE KGaA	0.6x	1.4%	€726.9m
NXU Nexus	4.5x	9.8%	€1.2b
AGE0 Agfa-Gevaert	0.09x	4.6%	€103.7m

Price-To-Sales vs Peers: AGE0 is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does AGE0's PS Ratio compare vs other companies in the European Healthcare Services Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	2.2x	8.5%
AGE0 Agfa-Gevaert	0.09x	4.6%	US$108.02m

6 Companies		Estimated Growth	Market Cap
Industry Avg.	2.2x	29.7%
AGE0 Agfa-Gevaert	0.09x	113.3%	US$108.02m

No more companies

Price-To-Sales vs Industry: AGE0 is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Healthcare Services industry average (2.2x).

Price to Sales Ratio vs Fair Ratio

What is AGE0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AGE0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.09x
Fair PS Ratio	0.5x

Price-To-Sales vs Fair Ratio: AGE0 is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

-5.5%

18.9%

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

-8.8%

-37.3%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

0.5%

-82.5%